使用阿仑单抗、氟达拉滨和美法仑进行预处理后，无关供者造血干细胞移植治疗先天性角化不良后的晚期死亡。 - Suppr

Suppr

超能文献

Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.

作者信息

Amarasinghe K, Dalley C, Dokal I, Laurie A, Gupta V, Marsh J

出版信息

Bone Marrow Transplant. 2007 Nov;40(9):913-4. doi: 10.1038/sj.bmt.1705839. Epub 2007 Aug 27.

DOI:10.1038/sj.bmt.1705839

PMID:17724438

Abstract

摘要

相似文献

Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.

Bone Marrow Transplant. 2007 Nov;40(9):913-4. doi: 10.1038/sj.bmt.1705839. Epub 2007 Aug 27.

Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.

Bone Marrow Transplant. 2011 Jan;46(1):98-104. doi: 10.1038/bmt.2010.65. Epub 2010 Apr 12.

Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.

Jpn J Clin Oncol. 2006 Jan;36(1):46-9. doi: 10.1093/jjco/hyi211. Epub 2006 Jan 19.

Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.

Bone Marrow Transplant. 2016 May;51(5):744-6. doi: 10.1038/bmt.2015.333. Epub 2016 Jan 25.

The relevance of nonmyeloablative transplants in developing countries: lessons from the UK experience.

Transplant Proc. 2003 Feb;35(1):172-3. doi: 10.1016/s0041-1345(02)03870-8.

A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.

Bone Marrow Transplant. 2012 Sep;47(9):1254-5. doi: 10.1038/bmt.2011.257. Epub 2012 Jan 16.

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.

Br J Haematol. 2005 Jun;129(5):631-43. doi: 10.1111/j.1365-2141.2005.05513.x.

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

Br J Haematol. 2007 Oct;139(1):70-80. doi: 10.1111/j.1365-2141.2007.06759.x.

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Bone Marrow Transplant. 2002 Dec;30(12):797-804. doi: 10.1038/sj.bmt.1703733.

Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.

Biol Blood Marrow Transplant. 2006 Jul;12(7):712-8. doi: 10.1016/j.bbmt.2006.03.002.

引用本文的文献

Haploidentical Hematopoietic Cell Transplantation in Dyskeratosis Congenita with Myelodysplastic Syndrome/Acute Myeloid Leukemia.

Blood Cell Ther. 2025 Feb 25;8(1):186-189. doi: 10.31547/bct-2024-022.

Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?

Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):141-148. doi: 10.1182/hematology.2023000471.

[Advances in research on childhood neutropenia].

Zhongguo Dang Dai Er Ke Za Zhi. 2017 Apr;19(4):484-489. doi: 10.7499/j.issn.1008-8830.2017.04.023.

Fatal Hemorrhagic Gastrointestinal Angioectasia after Bone Marrow Transplantation for Dyskeratosis Congenita.

Intern Med. 2016;55(23):3441-3444. doi: 10.2169/internalmedicine.55.7462. Epub 2016 Dec 1.

Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.

Int J Hematol. 2016 Apr;103(4):373-9. doi: 10.1007/s12185-016-1951-0. Epub 2016 Feb 12.

A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant. 2016 May;22(5):884-8. doi: 10.1016/j.bbmt.2016.01.026. Epub 2016 Feb 1.

A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition.

Aging (Albany NY). 2015 Nov;7(11):911-27. doi: 10.18632/aging.100835.

Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.

Bone Marrow Transplant. 2015 Sep;50(9):1168-72. doi: 10.1038/bmt.2015.117. Epub 2015 Jun 8.

Bone marrow failure and the telomeropathies.

Blood. 2014 Oct 30;124(18):2775-83. doi: 10.1182/blood-2014-05-526285. Epub 2014 Sep 18.

Inherited bone marrow failure syndromes in adolescents and young adults.

Ann Med. 2014 Sep;46(6):353-63. doi: 10.3109/07853890.2014.915579. Epub 2014 Jun 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验